Contineum Therapeutics (CTNM) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Oculis (OCS) over the past year, gaining 12.6% versus a loss of 60.5%. Oculis is the larger company by market cap ($513.6 million vs $503.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | OCS |
|---|---|---|
| Share price | $13.38 | $8.34 |
| Market cap | $503.37M | $513.64M |
| 1-day change | +1.52% | -3.70% |
| YTD return | +17.06% | -58.24% |
| 1-year return | +12.63% | -60.46% |
| 5-year return | — | -15.07% |
| EPS (TTM) | $-1.73 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.79 | $34.48 |
| 52-week low | $8.60 | $8.30 |
| Distance from 52-week high | -24.77% | -75.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.64% | +340.29% |
| Average volume | 526.32K | 256.38K |
| Shares outstanding | 32.96M | 61.59M |
| Employees | 51 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed OCS by 73.1 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
CTNM vs OCS FAQ
Which is bigger, Contineum Therapeutics or Oculis?
Oculis (OCS) is larger, with a market capitalization of $513.64M compared with $503.37M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CTNM or OCS?
CTNM returned +12.63% over the past 12 months, compared with -60.46% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.